Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • News

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

By Benzinga Newsdesk
December 14, 9:38 AM
Journal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy metabolites in multiple sclerosis and Parkinson's disease with

CLNN

Read More
3 minute read
  • Biotech
  • General
  • News

SELLAS Life Sciences Announces First Patients Enrolled In 60 mg Dose Cohort In Phase 2a Clinical Trial Of SLS009 In Acute Myeloid Leukemia

By Benzinga Newsdesk
December 14, 9:31 AM
- Enrollment Completed in 45 mg Safety Cohort; Safety Monitoring Committee Advocated Proceeding to Recommended Phase 2 Dose Level of 60 mg -- Patients in 60 mg Dose Cohort Will be Dosed with 60 mg Once per Week or

SLS

Read More
2 minute read
  • Biotech
  • General
  • News

Applied DNA Announces Joint Development Agreement To Integrate Linea IVT Platform Into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow

By Benzinga Newsdesk
December 14, 9:09 AM
- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times -STONY BROOK, NY and NEEDHAM, MA / ACCESSWIRE

APDN

Read More
2 minute read
  • Biotech
  • General
  • News

Rani Therapeutics Announces Preclinical Pharmacodynamic Data On Transenteric Delivery Of GLP-1 Incretin Triagonist

By Benzinga Newsdesk
December 14, 9:09 AM
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –- Preclinical data support the potential for the RaniPill platform to enable oral delivery of

RANI

Read More
1 minute read
  • FDA
  • General
  • Health Care
  • Large Cap
  • News

Medtronic’s PulseSelect PFA System Gets FDA Nod, Revolutionizing Atrial Fibrillation Treatment in US

By Vandana Singh
December 14, 8:39 AM
The FDA approved Medtronic plc's (NYSE: MDT) PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF), an irregular and often 

MDT

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • M&A
  • News
  • Penny Stocks

Rain Oncology Goes Private Just Two Years After $120M NASDAQ Debut

By Vandana Singh
December 14, 8:26 AM
Rain Oncology Inc (NASDAQ: RAIN) has agreed to be acquired by Pathos AI Inc.

JNJ

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Legal
  • News

Supreme Court Set to Decide Future of Mifepristone: Showdown Looms Over FDA’s Endorsement

By Vandana Singh
December 13, 2:44 PM
The U.S. Supreme Court is set to deliberate on the future of mifepristone, a crucial drug employed in over half of all abortions within the U.S. 

CI

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Initiation
  • Markets
  • News
  • Price Target
  • Small Cap
  • Trading Ideas

Arcturus Therapeutics’ Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside

By Vandana Singh
December 13, 2:34 PM
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.

ARCT

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Obesity Drugs: Employers Embrace Virtual Healthcare to Manage Surging Costs

By Vandana Singh
December 13, 2:28 PM
U.S.

BA

Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • Markets
  • Movers
  • News

Vertex’s Non-Opioid Diabetes Associated Nerve Pain Treatment Candidate Aces Mid-Stage Trial

By Vandana Singh
December 13, 1:30 PM
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) released results from its Phase 2 dose-ranging study of VX-548 (non-opioid pain medicine) for diabetic peripheral neuropathy, a type of nerve damage 

VRTX

Posts pagination

Previous 1 … 162 163 164 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service